turnaround times existing tests already causing delays optimal treatments.
steps minister taking ensure enough capacity ever- increasing demand diagnostic tests?
national cancer strategy needs thoroughly scrutinised final draft published, ensure measures demanded cancer charities patient groups, ideas life sciences sector, properly covered.
nhs performance must measured regularly lifetime strategy see improvements actually made.
minister explain accountability mechanisms considered national cancer strategy?
thank.
member edinburgh south west bringing bill house.
rise support.
friend member edinburgh south west( dr arthur).
know put huge amount effort bringing bill house, collaboration many others, including patients, families, professionals charities.
send condolences, wife family death father-- law, tilly' family.
lose child unbearable natural order things.
bill much needed welcome opportunity make observations., refer.
friend member calder valley( josh fenton- glynn) brother.
live area lunt referred, going remarkable legacy brother: area rewilded forest due course, absolutely fantastic.
invite family come down—i show around see legacy brother left.
also want refer comments made chief executive officer brain tumour charity, dr michele afif, context bill house.
online article last month, wrote: “during clinical career frequently moved courage determination patients families.
behoves support endeavours.
friend member edinburgh south west help people “don’t voice”, dr afif says, giving unambiguous backing calls “a bill hope.
must ensure hope turned reality: job every member chamber.
owe affected rare cancers champion needs, treatment lives.
proposed legislation would starting point—a first base.
enable facilitate promotion research rare cancers better access clinical trials, said, initiate review marketing authorisations- called orphan products, explore detail.
devastating cancer diagnosis.
know family members diagnosed one form another.
shock trauma comes news hard take,.
member wokingham( clive jones) said.
find subsequently spectrum intervention medicines allied interventions limited rare nature particular cancer surely adds distress worry.. member esher walton( monica harding).
friend member mitcham morden( dame siobhain mcdonagh) said, glioblastoma, questions inevitably sweep minds affected whether appropriate medicinal intervention available even horizon.
orphan products drugs used treat rare cancers rare diseases.
pharmaceutical industry reluctant develop drugs cost, time effort commercially productive, given number people use.
fact potentially lifesaving, life- changing, drugs produced leaves significant lacuna treatment options rare cancers.
although public health need—of absolutely doubt—there resource enable lacuna filled.
resource made available.
therefore pleased clause bill place duty secretary state health social care undertake review law relating marketing authorisations potential orphan medicines.
note bill require assessment regulatory approaches countries, also welcome.
excellent much- needed step right direction, linked requirements bill relating research programmes initiatives.
sends clear unambiguous message affected affected—that could anybody chamber, heard, people chamber—that government heard said listening message plea, taking practical action put effect, welcome.
countries introduced similar legislation respect.
provision clause() help form progressive, informed approach requirements enable information, practices protocols jurisdictions harvested.
example, genetic alliance points many, 000 rare diseases—possibly more—affecting one 17 people, approved treatments available one 20 rare diseases generally.
although significant cohorts people per se particular disease category, collectively millions people affected one fashion another rare disease, including rare cancers—and less case rare cancers: disease disease, affected, whether rare, entitled equity care intervention.
case, potential interventions cannot simply left market arrangements.
important facilitate comprehensive approach development orphan medicines, must set context, example, 2022 survey 61 orphan medicines received eu approvals 2018 2021., 36 orphan medicines made available england, compared 55 germany, 50 italy, 48 france 31 spain.
medicines specifically relate cancer, helps contextualise difference numbers orphan medicines.
research programme 2020 2025 university sheffield, funded wellcome trust, indicated: “furthermore, third eu authorised orphan drugs recommended nice… thus, medical needs rare disease patients potentially underserved compared eu.
indeed, programme called orphanisation project.
clearly, university puts, “major international debate…currently ongoing might improve patients' access orphan drugs, raising important questions value medicines, ethics resource allocation”.
project sets path creative progressing relatively new concept orphanisation, “as way understanding contemporary changes biopharmaceutical sector.
specifically, project examines extent orphanisation occurring eu,, usa”, seeks understand informed “different technologies, institutions, actors, addressing implications industry, health policy patients”.
look forward progress make.
believe proposals bill help.
follow systemically consistently change scenario better.